Prof. Jacques H. Grosset

(Reading, Writing, Speaking)

• Nuermberger E, Tyagi S, Tasneen R, Williams KN, Almeida D, Rosenthal I, Grosset JH (2008) Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin and pyrazinamide in a murine model of tuberculosis, Antimicrob Agents Chemother, 52 (4), In Press
• Rosenthal IA, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL (2007) Daily dosing of rifapentine cures tuberculosis in three months months or less in the murine model, PLoS Medicine, 4 (12), 0001-0008
• Almeida D, Nuermberger E, Tyagi S, Bishai WR, Grosset J (2007) In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis, Antimicrob Agents Chemother, 51 (12), 4261-4266
• Chauty A, Ardant MF, Adeye A, Euverte H, Guedenon A, Johnson C, Aubry J, Nuermberger E, Grosset J (2007) Promising clinical efficact of the combination streptomycin-rifampin for the treatment of Buruli ulcer (Mycobacterium ulcerans disease)y, Antimicrob Agents Chemother, 51 (11), 4029-4035
• Rosenthal IM, Williams K, Tyagi S, Peloquin CA, Vernon AA, Bishai WR, Grosset JH, Nuermberger EL (2006) Potent twice-weekly rifapentine-containing regimens in murine tuberculosis, Am J Resp Crit care Med, 174, 94-101
• Nuermberger E,Rosenthal I, Tyagi S, Williams KN, Almeida D, PeloquinCA, Bishai WR, Grosset JH (2006) Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis, Antimicrob Agents Chemotherapy, 50, 2621-2625
• Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, Phillips R, Evans M, Ofori-Adjei D, Klustse E, Owusu-Boateng J, Amedofu GK, Awuah P, Ampadu E, Amofah G, Asiedu K, Wansbrough-Jones M (Aug 2005) Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans, Antimicrobial Agents and Chemotherapy, 49 (8), 3182-6
• Tyagi S, Nuermberger E, Yoshimatsu T, Williams K, Rosenthal I, Lounis N, Bishai W, Grosset J (Jun 2005) Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis, Antimicrobial Agents and Chemotherapy, 49 (6), 2289-93
• Ginsburg AS, Lee J, Woolwine SC, Grosset JH, Hamzeh FM, Bishai WR (Feb 2005) Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system, Antimicrobial Agents and Chemotherapy, 49 (2), 853-6
• Casal M, Vaquero M, Rinder H, Tortoli E, Grosset J, Rusch-Gardes S, Gutierrez J, Jarlier V. (2005) A case-control study for multi-drug resistant tuberculosis: risk factors in four European countries, Microbial drug resistance, 11, 61-66
• Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien RJ, Vernon AA, Chaisson RE, Bishai WR, Grosset JH (Nov 2004) Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis, American Journal of Respiratory and Critical Care Medicine, 170 (10), 1131-4
• Drenou B, Tilanus M, Semana G, Alizadeh M, Birebent B, Grosset JM, Dias P, van Wichen D, Arts Y, De Santis D, Fauchet R, Amiot L (Oct 2004) Loss of heterozygosity, a frequent but a non-exclusive mechanism responsible for HLA dysregulation in non-Hodgkin's lymphomas, British Journal of Haematology, 127 (1), 40-9
• Karakousis PC, Yoshimatsu T, Lamichhane G, Woolwine SC, Nuermberger EL, Grosset J, Bishai WR (Sep 2004) Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice, The Journal of Experimental Medicine, 200 (5), 647-57
• Nuermberger E, Grosset J (Apr 2004) Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections, European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology, 23 (4), 243-55
• Nuermberger EL, Yoshimatsu T, Tyagi S, Bishai WR, Grosset JH (Feb 2004) Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG, Infection and Immunity, 72 (2), 1065-71
• Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH (Feb 2004) Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis, American Journal of Respiratory and Critical Care Medicine, 169 (3), 421-6
• Ginsburg AS, Grosset JH, Bishai WR (Jul 2003) Fluoroquinolones, tuberculosis, and resistance, The Lancet Infectious Diseases, 3 (7), 432-42
• Quy HT, Lan NT, Borgdorff MW, Grosset J, Linh PD, Tung LB, van Soolingen D, Raviglione M, Co NV, Broekmans J (Jul 2003) Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate?, The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease, 7 (7), 631-6
• Lounis N, Maslo C, Truffot-Pernot C, Grosset J, Boelaert RJ (Jun 2003) Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis, The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease, 7 (6), 575-9
• Lamichhane G, Zignol M, Blades NJ, Geiman DE, Dougherty A, Grosset J, Broman KW, Bishai WR (Jun 2003) A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis, Proceedings of the National Academy of Sciences of the United States of America, 100 (12), 7213-8
• Emmanuelli X, Grosset J (Apr 2003) [Tuberculosis and poverty], Revue Des Maladies Respiratoires, 20 (2 Pt 1), 169-71
• Grosset J (Mar 2003) Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary, Antimicrobial Agents and Chemotherapy, 47 (3), 833-6
• Dega H, Bentoucha A, Robert J, Jarlier V, Grosset J (Oct 2002) Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice, Antimicrobial Agents and Chemotherapy, 46 (10), 3193-6
• Yoshimatsu T, Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J (Jun 2002) Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis, Antimicrobial Agents and Chemotherapy, 46 (6), 1875-9
• Grosset J, Zunic L, Morcrette C (Mar 2002) [World epidemiology of tuberculosis and resistance against anti-tuberculosis drugs], Annales De Medecine Interne, 153 (2), 107-12
• Grosset JH, Cole ST (Dec 2001) Genomics and the chemotherapy of leprosy, Leprosy Review, 72 (4), 429-40
• Honore N, Roche PW, Grosset JH, Cole ST (Dec 2001) A method for rapid detection of rifampicin-resistant isolates of Mycobacterium leprae, Leprosy Review, 72 (4), 441-8
• Lounis N, Bentoucha A, Truffot-Pernot C, Ji B, O'Brien RJ, Vernon A, Roscigno G, Grosset J (Dec 2001) Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice, Antimicrobial Agents and Chemotherapy, 45 (12), 3482-6
• Lounis N, Truffot-Pernot C, Bentoucha A, Robert J, Ji B, Grosset J (Nov 2001) Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice, Antimicrobial Agents and Chemotherapy, 45 (11), 3229-30
• Bentoucha A, Robert J, Dega H, Lounis N, Jarlier V, Grosset J (Nov 2001) Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice, Antimicrobial Agents and Chemotherapy, 45 (11), 3109-12
• Astagneau P, Desplaces N, Vincent V, Chicheportiche V, Botherel A, Maugat S, Lebascle K, Leonard P, Desenclos J, Grosset J, Ziza J, Brucker G (Sep 2001) Mycobacterium xenopi spinal infections after discovertebral surgery: investigation and screening of a large outbreak, Lancet, 358 (9283), 747-51
• Grosset JH (Jun 2001) Newer drugs in leprosy, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 69 (2 Suppl), S14-8
• Boelaert JR, Appelberg R, Gomes MS, Blasi E, Mazzolla R, Grosset J, Lounis N, Soteriadou K, Thiakaki M, Taramelli D, Tognazioli C (Mar 2001) Experimental results on chloroquine and AIDS-related opportunistic infections, Journal of Acquired Immune Deficiency Syndromes (1999), 26 (3), 300-1
• Lounis N, Truffot-Pernot C, Grosset J, Gordeuk VR, Boelaert JR (Feb 2001) Iron and Mycobacterium tuberculosis infection, Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology, 20 (3), 123-6
• Grosset J (Dec 2000) The new challenges for chemotherapy research, Leprosy Review, 71 Suppl, S100-4
• Ji B, Grosset J (Dec 2000) Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy, Leprosy Review, 71 Suppl, S81-7
• Nguyen LN, Cartel JL, Grosset JH (Dec 2000) Chemoprophylaxis of leprosy in the southern Marquesas with a single 25 mg/kg dose of rifampicin. Results after 10 years, Leprosy Review, 71 Suppl, S33-5; discussion S3
• Cambau E, Truffot-Pernot C, Boulahbal F, Wichlacz C, Grosset J, Jarlier V (Dec 2000) Mycobacterial growth indicator tube versus the proportion method on Lowenstein-Jensen medium for antibiotic susceptibility testing of Mycobacterium tuberculosis, European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology, 19 (12), 938-42
• Consigny S, Bentoucha A, Bonnafous P, Grosset J, Ji B (Oct 2000) Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice, Antimicrobial Agents and Chemotherapy, 44 (10), 2919-21
• Dega H, Robert J, Bonnafous P, Jarlier V, Grosset J (Sep 2000) Activities of several antimicrobials against Mycobacterium ulcerans infection in mice, Antimicrobial Agents and Chemotherapy, 44 (9), 2367-72
• Dega H, Chosidow O, Barete S, Carbonnelle B, Grosset J, Jarlier V (Sep 2000) [Mycobacterium ulcerans infection], Annales De Medecine Interne, 151 (5), 339-44
• Robert J, Trystram D, Truffot-Pernot C, Carbonnelle B, Grosset J (Jul 2000) Surveillance of Mycobacterium tuberculosis drug resistance in France, 1995-1997. AZAY Mycobacteria Study Group, The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease, 4 (7), 665-72
• Robert J, Trystram D, Truffot-Pernot C, Cambau E, Jarlier V, Grosset J (Jun 2000) Twenty-five years of tuberculosis in a French university hospital: a laboratory perspective, The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease, 4 (6), 504-12
• Daniel N, Lounis N, Ji B, O'Brien RJ, Vernon A, Geiter LJ, Szpytma M, Truffot-Pernot C, Hejblum G, Grosset J (May 2000) Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens, American Journal of Respiratory and Critical Care Medicine, 161 (5), 1572-7
• Ji B, Grosset JH (Dec 1999) Drugs and regimens for preventive therapy against tuberculosis, disseminated Mycobacterium avium complex infection and leprosy, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 67 (4 Suppl), S45-55
• Flament-Saillour M, Robert J, Jarlier V, Grosset J (Aug 1999) Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study, American Journal of Respiratory and Critical Care Medicine, 160 (2), 587-93
• Robert J, Boulahbal F, Trystram D, Truffot-Pernot C, de Benoist AC, Vincent V, Jarlier V, Grosset J (Aug 1999) A national survey of human Mycobacterium bovis infection in France. Network of Microbiology Laboratories in France, The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease, 3 (8), 711-4
• Rinder H, Feldmann K, Tortoli E, Grosset J, Casal M, Richter E, Rifai M, Jarlier V, Vaquero M, Rusch-Gerdes S, Cambau E, Gutierrez J, Loscher T (Jun 1999) Culture-independent prediction of isoniazid resistance in Mycobacterium tuberculosis by katG gene analysis directly from sputum samples, Molecular Diagnosis : a Journal Devoted to the Understanding of Human Disease Through the Clinical Application of Molecular Biology, 4 (2), 145-52
• Grosset J (1999) [Leprosy and tuberculosis: opposite results?], Medecine Tropicale : Revue Du Corps De Sante Colonial, 59 (2 Suppl), 25-30
• Grosset J (1999) [Which strategies for eradication of tuberculosis?], Bulletin De L'academie Nationale De Medecine, 183 (7), 25-37; discussion 37
• Grosset JH, Franzblau S ( Dec 1998) Report of workshop on chemotherapy, , , 595-6 pages
• Craft JC, Notario GF, Grosset JH, Heifets LB (Oct 1998) Clarithromycin resistance and susceptibility patterns of Mycobacterium avium strains isolated during prophylaxis for disseminated infection in patients with AIDS, Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 27 (4), 807-12
• Jouveshomme S, Cambau E, Trystram D, Szpytma M, Sougakoff W, Derenne JP, Grosset J (Oct 1998) Clinical utility of an amplification test based on ligase chain reaction in pulmonary tuberculosis, American Journal of Respiratory and Critical Care Medicine, 158 (4), 1096-101
• Carbonne A, Lemaitre N, Bochet M, Truffot-Pernot C, Katlama C, Grosset J, Bricaire F, Jarlier V (Oct 1998) Mycobacterium avium complex common-source or cross-infection in AIDS patients attending the same day-care facility, Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America, 19 (10), 784-6
• Grosset J, [What's new for tuberculosis in 1998?], La Revue De Medecine Interne / Fondee ... Par La Societe Nationale Francaise De Medecine Interne, 19(9), 613-6, Sep 1998
• Schwoebel V, Decludt B, de Benoist AC, Haeghebaert S, Torrea G, Vincent V, Grosset J (Sep 1998) Multidrug resistant tuberculosis in France 1992-4: two case-control studies, Bmj (clinical Research Ed.), 317 (7159), 630-1
• Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J (Aug 1998) In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis, Antimicrobial Agents and Chemotherapy, 42 (8), 2066-9
• Ji B, Sow S, Perani E, Lienhardt C, Diderot V, Grosset J (May 1998) Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients, Antimicrobial Agents and Chemotherapy, 42 (5), 1115-20
• Grosset J, Lounis N, Truffot-Pernot C, O'Brien RJ, Raviglione MC, Ji B (May 1998) Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice, American Journal of Respiratory and Critical Care Medicine, 157 (5 Pt 1), 1436-40
• Lemaitre N, Sougakoff W, Truffot-Pernot C, Cambau E, Derenne JP, Bricaire F, Grosset J, Jarlier V (May 1998) Use of DNA fingerprinting for primary surveillance of nosocomial tuberculosis in a large urban hospital: detection of outbreaks in homeless people and migrant workers, The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease, 2 (5), 390-6
• Grosset J, Truffot-Pernot C (Apr 1998) [Mycobacterium xenopi, a newcomer?], La Revue Du Praticien, 48 (7), 701-3
• Wyplosz B, Truffot-Pernot C, Robert J, Jarlier V, Grosset J (Dec 1997) [The bacteriology of tuberculosis and non-tuberculosis mycobacterial infections], Revue Des Maladies Respiratoires, 14 Suppl 5, S33-48
• Ji B, Jamet P, Sow S, Perani EG, Traore I, Grosset JH (Sep 1997) High relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks, Antimicrobial Agents and Chemotherapy, 41 (9), 1953-6
• May T, Brel F, Beuscart C, Vincent V, Perronne C, Doco-Lecompte T, Saint-Marc T, Dautzenberg B, Grosset J (Sep 1997) Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium Group. Agence Nationale de Recherche sur le Sida, Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 25 (3), 621-9
• Mane I, Cartel JL, Grosset JH (Jun 1997) Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 65 (2), 224-9
• Grosset J, Alary R, Gautier MF, Menossi M, Martinez-Izquierdo JA, Joudrier P (May 1997) Characterization of a barley gene coding for an alpha-amylase inhibitor subunit (CMd protein) and analysis of its promoter in transgenic tobacco plants and in maize kernels by microprojectile bombardment, Plant Molecular Biology, 34 (2), 331-8
• Lounis N, Ji B, Truffot-Pernot C, Grosset J (Mar 1997) Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice?, Antimicrobial Agents and Chemotherapy, 41 (3), 607-10
• Grosset J, Ji B (1997) Prevention of the selection of clarithromycin-resistant Mycobacterium avium-intracellulare complex, Drugs, 54 Suppl 2, 23-7; discussion 28-
• Iborra C, Cambau E, Lecomte C, Grosset J, Bricaire F, Caumes E (1997) [Cutaneous tuberculosis. A study of 4 cases], Annales De Dermatologie Et De Venereologie, 124 (2), 139-43
• Dautzenberg B, Truffot-Pernot C, Hazebroucq J, Legris S, Guerin C, Begelman C, Guermonprez G, Fievet MH, Chastang C, Grosset J (Jan-Feb 1997) A randomized comparison of two clarithromycin doses for treatment of Mycobacterium avium complex infections, Infection, 25 (1), 16-21
• Grosset J (Apr-Jun 1997) Whither short-course chemotherapy for leprosy?, Indian Journal of Leprosy, 69 (2), 119-20
• Ji B, Levy L, Grosset JH (Dec 1996) Chemotherapy of leprosy: progress since the Orlando Congress, and prospects for the future, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 64 (4 Suppl), S80-8; discussion S8
• Lemaitre N, Sougakoff W, Coetmeur D, Vaucel J, Jarlier V, Grosset J (Dec 1996) Nosocomial transmission of tuberculosis among mentally-handicapped patients in a long-term care facility, Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease, 77 (6), 531-6
• Ji B, Jamet P, Perani EG, Sow S, Lienhardt C, Petinon C, Grosset JH (Sep 1996) Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients, Antimicrobial Agents and Chemotherapy, 40 (9), 2137-41
• Doucet-Populaire F, Lalande V, Carpentier E, Bourgoin A, Dailloux M, Bollet C, Vachee A, Moinard D, Texier-Maugein J, Carbonnelle B, Grosset J (Aug 1996) A blind study of the polymerase chain reaction for the detection of Mycobacterium tuberculosis DNA. Azay Mycobacteria Study Group, Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease, 77 (4), 358-62
• Grosset J (Jun 1996) [Bacteriological diagnosis of tuberculosis], La Revue Du Praticien, 46 (11), 1337-43
• Traore I, Ji B, Lienhardt C, Bobin P, Grosset J (Jun 1996) Determination of the minimal effective dosages of ofloxacin and sparfloxacin against M. leprae in the mouse foot pad system, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 64 (2), 142-5
• Lemaitre N, Sougakoff W, Truffot C, Grosset J, Jarlier V (May 1996) [Analysis of restriction fragment length polymorphism (RFLP) of Mycobacterium tuberculosis strains isolated from patients with several episodes of tuberculosis], Pathologie-biologie, 44 (5), 452-5
• Ji B, Perani EG, Petinom C, Grosset JH (Feb 1996) Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice, Antimicrobial Agents and Chemotherapy, 40 (2), 393-9
• Ji B, Lounis N, Truffot-Pernot C, Grosset J (Feb 1996) How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice?, Antimicrobial Agents and Chemotherapy, 40 (2), 437-42
• Grosset J (Jan-Feb 1996) Current problems with tuberculosis treatment, Research in Microbiology, 147 (1-2), 10-6
• Truffot-Pernot C, Lounis N, Grosset JH, Ji B (Dec 1995) Clarithromycin is inactive against Mycobacterium tuberculosis, Antimicrobial Agents and Chemotherapy, 39 (12), 2827-8
• Chaulet P, Boulahbal F, Grosset J (Dec 1995) Surveillance of drug resistance for tuberculosis control: why and how?, Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease, 76 (6), 487-92
• Enarson DA, Grosset J, Mwinga A, Hershfield ES, O'Brien R, Cole S, Reichman L ( Sep 1995) The challenge of tuberculosis: statements on global control and prevention, , , 809-19 pages
• Doucet-Populaire F, Truffot-Pernot C, Grosset J, Jarlier V (Jul 1995) Acquired resistance in Mycobacterium avium complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin, The Journal of Antimicrobial Chemotherapy, 36 (1), 129-36
• Grosset J, Mouton Y (Jun 1995) Is PCR a useful tool for the diagnosis of tuberculosis in 1995?, Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease, 76 (3), 183-4
• Ji B, Lounis N, Truffot-Pernot C, Grosset J (Jun 1995) In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis, Antimicrobial Agents and Chemotherapy, 39 (6), 1341-4
• Struillou L, Cohen Y, Lounis N, Bertrand G, Grosset J, Vilde JL, Pocidalo JJ, Perronne C (Apr 1995) Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice, Antimicrobial Agents and Chemotherapy, 39 (4), 878-81
• Lounis N, Ji B, Truffot-Pernot C, Grosset J (Mar 1995) Selection of clarithromycin-resistant Mycobacterium avium complex during combined therapy using the beige mouse model, Antimicrobial Agents and Chemotherapy, 39 (3), 608-12
• Cohen Y, Perronne C, Lazard T, Truffot-Pernot C, Grosset J, Vilde JL, Pocidalo JJ (Mar 1995) Use of normal C57BL/6 mice with established Mycobacterium avium infections as an alternative model for evaluation of antibiotic activity, Antimicrobial Agents and Chemotherapy, 39 (3), 735-8
• Ji B, Lounis N, Truffot-Pernot C, Grosset J (Nov 1994) Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model, Antimicrobial Agents and Chemotherapy, 38 (11), 2521-9
• Cambau E, Sougakoff W, Besson M, Truffot-Pernot C, Grosset J, Jarlier V (Nov 1994) Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin, The Journal of Infectious Diseases, 170 (5), 1351
• Chapuis L, Ji B, Truffot-Pernot C, O'Brien RJ, Raviglione MC, Grosset JH (Nov 1994) Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice, American Journal of Respiratory and Critical Care Medicine, 150 (5 Pt 1), 1355-62
• Cambau E, Sougakoff W, Besson M, Truffot-Pernot C, Grosset J, Jarlier V (Aug 1994) Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin, The Journal of Infectious Diseases, 170 (2), 479-83
• Lazard T, Perronne C, Truffot-Pernot C, Grosset J, Vilde JL, Pocidalo JJ (Aug 1994) Chloroquine does not enhance the activity of clarithromycin against multiplication of Mycobacterium avium within human macrophages, Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease, 75 (4), 283-5
• Heym B, Honore N, Truffot-Pernot C, Banerjee A, Schurra C, Jacobs WR Jr, van Embden JD, Grosset JH, Cole ST (Jul 1994) Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study, Lancet, 344 (8918), 293-8
• Grosset JH (Jun 1994) Progress in the chemotherapy of leprosy, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 62 (2), 268-77
• Grosset JH (Apr 1994) Assessment of new therapies for infection due to the Mycobacterium avium complex: appropriate use of in vitro and in vivo testing, Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 18 Suppl 3, S233-6
• Ji B, Perani EG, Petinom C, N'Deli L, Grosset JH (Apr 1994) Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy, Antimicrobial Agents and Chemotherapy, 38 (4), 662-7
• Xiong JH, Ji B, Perani EG, Petinon C, Grosset JH (Mar 1994) Further study of the effectiveness of single doses of clarithromycin and minocycline against Mycobacterium leprae in mice, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 62 (1), 37-42
• Schwoebel V, Hubert B, Grosset J (Feb 1994) Tuberculous meningitis in France in 1990: characteristics and impact of BCG vaccination, Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease, 75 (1), 44-8
• Vareldzis BP, Grosset J, de Kantor I, Crofton J, Laszlo A, Felten M, Raviglione MC, Kochi A (Feb 1994) Drug-resistant tuberculosis: laboratory issues. World Health Organization recommendations, Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease, 75 (1), 1-7
• Honore N, Perrani E, Telenti A, Grosset J, Cole ST (Dec 1993) A simple and rapid technique for the detection of rifampin resistance in Mycobacterium leprae, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 61 (4), 600-4
• Ji B, Truffot-Pernot C, Lacroix C, Raviglione MC, O'Brien RJ, Olliaro P, Roscigno G, Grosset J (Dec 1993) Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice, The American Review of Respiratory Disease, 148 (6 Pt 1), 1541-6
• Hejblum G, Jarlier V, Grosset J, Aurengo A (Sep 1993) Automated interpretation of disk diffusion antibiotic susceptibility tests with the radial profile analysis algorithm, Journal of Clinical Microbiology, 31 (9), 2396-401
• Lazard T, Perronne C, Grosset J, Vilde JL, Pocidalo JJ (Aug 1993) Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with Mycobacterium avium, Antimicrobial Agents and Chemotherapy, 37 (8), 1690-2
• Ji B, Jamet P, Perani EG, Bobin P, Grosset JH (Jul 1993) Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy, The Journal of Infectious Diseases, 168 (1), 188-90
• Glaziou P, Cartel JL, Moulia-Pelat JP, Ngoc LN, Chanteau S, Plichart R, Grosset JH (Jun 1993) Tuberculosis in leprosy patients detected between 1902 and 1991 in French Polynesia, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 61 (2), 199-204
• Lazard T, Perronne C, Cohen Y, Grosset J, Vilde JL, Pocidalo JJ (Apr 1993) Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice, Antimicrobial Agents and Chemotherapy, 37 (4), 692-5
• Lalande V, Truffot-Pernot C, Paccaly-Moulin A, Grosset J, Ji B (Mar 1993) Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice, Antimicrobial Agents and Chemotherapy, 37 (3), 407-13
• Dautzenberg B, Saint Marc T, Meyohas MC, Eliaszewitch M, Haniez F, Rogues AM, De Wit S, Cotte L, Chauvin JP, Grosset J (Feb 1993) Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome, Archives of Internal Medicine, 153 (3), 368-72
• Grosset JH (Dec 1992) Treatment of tuberculosis in HIV infection, Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease, 73 (6), 378-83
• Ji B, Perani EG, Petinon C, Grosset JH (Dec 1992) Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 60 (4), 556-61
• Ji B, Lounis N, Truffot-Pernot C, Grosset J (Dec 1992) Selection of resistant mutants of Mycobacterium avium in beige mice by clarithromycin monotherapy, Antimicrobial Agents and Chemotherapy, 36 (12), 2839-40
• Perronne C, Cohen Y, Truffot-Pernot C, Grosset J, Vilde JL, Pocidalo JJ (Nov 1992) Sparfloxacin, ethambutol, and cortisol receptor inhibitor RU-40 555 treatment for disseminated Mycobacterium avium complex infection of normal C57BL/6 mice, Antimicrobial Agents and Chemotherapy, 36 (11), 2408-12
• Rouby JJ, Martin De Lassale E, Poete P, Nicolas MH, Bodin L, Jarlier V, Le Charpentier Y, Grosset J, Viars P (Oct 1992) Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects, The American Review of Respiratory Disease, 146 (4), 1059-66
• Cohen Y, Perronne C, Truffot-Pernot C, Grosset J, Vilde JL, Pocidalo JJ (Oct 1992) Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages, Antimicrobial Agents and Chemotherapy, 36 (10), 2104-7
• Schwoebel V, Hubert B, Grosset J (Sep 1992) Impact of BCG on tuberculous meningitis in France in 1990, Lancet, 340 (8819), 611
• Cartel JL, Boutin JP, Spiegel A, Glaziou P, Plichart R, Cardines R, Grosset JH (Sep 1992) Leprosy in French Polynesia. Epidemiological trends between 1946 and 1987, Leprosy Review, 63 (3), 211-22
• Cartel JL, Spiegel A, Nguyen Ngoc L, Moulia-Pelat JP, Martin PM, Grosset JH (Sep 1992) Leprosy in French Polynesia. The possible impact of multidrug therapy on epidemiological trends, Leprosy Review, 63 (3), 223-30
• Couderc LJ, Epardeau B, Dazza MC, Clauvel JP, Autran B, Grosset J, Caubarrere I (Sep 1992) Disseminated Mycobacterium avium intracellulare infection without predisposing conditions, Lancet, 340 (8821), 731
• Cartel JL, Chanteau S, Moulia-Pelat JP, Plichart R, Glaziou P, Boutin JP, Roux JF, Grosset JH (Sep 1992) Chemoprophylaxis of leprosy with a single dose of 25 mg per kg rifampin in the southern Marquesas; results after four years, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 60 (3), 416-20
• Pretet S, Lebeaut A, Parrot R, Truffot C, Grosset J, Dinh-Xuan AT (Jun 1992) Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. G.E.T.I.M. (Group for the Study and Treatment of Resistant Mycobacterial Infection), The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology, 5 (6), 680-4
• Grosset J, Truffot-Pernot C, Lacroix C, Ji B (Mar 1992) Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice, Antimicrobial Agents and Chemotherapy, 36 (3), 548-51
• Ji B, Truffot-Pernot C, Grosset J (Sep 1991) In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis, Tubercle, 72 (3), 181-6
• Dautzenberg B, Truffot C, Mignon A, Rozenbaum W, Katlama C, Perronne C, Parrot R, Grosset J (Sep 1991) Rifabutin in combination with clofazimine, isoniazid and ethambutol in the treatment of AIDS patients with infections due to opportunist mycobacteria. Groupe d'Etude et de Traitement des Infections a Mycobacteries Resistantes, Tubercle, 72 (3), 168-75
• Dautzenberg B, Truffot C, Legris S, Meyohas MC, Berlie HC, Mercat A, Chevret S, Grosset J (Sep 1991) Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial, The American Review of Respiratory Disease, 144 (3 Pt 1), 564-9
• Truffot-Pernot C, Ji B, Grosset J (Aug 1991) Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex, Antimicrobial Agents and Chemotherapy, 35 (8), 1677-8
• Perronne C, Gikas A, Truffot-Pernot C, Grosset J, Vilde JL, Pocidalo JJ (Jul 1991) Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages, Antimicrobial Agents and Chemotherapy, 35 (7), 1356-9
• Constant-Desportes M, Guelpa-Lauras CC, Carolina JC, Leoture A, Grosset JH, Sansarricq H (Jun 1991) A case of relapse with drug-susceptible M. leprae after multidrug therapy, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 59 (2), 242-7
• Ji B, Perani EG, Grosset JH (Mar 1991) Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice, Antimicrobial Agents and Chemotherapy, 35 (3), 579-81
• Ji B, Grosset JH (Dec 1990) Recent advances in the chemotherapy of leprosy, Leprosy Review, 61 (4), 313-29
• Chanteau S, Cartel JL, Perani E, N'Deli L, Roux J, Grosset JH (Dec 1990) Relationships between PGL-1 antigen in serum, tissue and viability of Mycobacterium leprae as determined by mouse footpad assay in multibacillary patients during short-term clinical trial, Leprosy Review, 61 (4), 330-40
• Grosset J (Sep 1990) [Norfloxacin: a broad-spectrum quinolone for superficial eye infections], Pathologie-biologie, 38 (7), 735-41
• Cartel JL, Chanteau S, Boutin JP, Plichart R, Richez P, Roux JF, Grosset JH (Sep 1990) Assessment of anti-phenolic glycolipid-I IgM levels using an ELISA for detection of M. leprae infection in populations of the South Pacific Islands, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 58 (3), 512-7
• Perronne C, Gikas A, Truffot-Pernot C, Grosset J, Pocidalo JJ, Vilde JL (Aug 1990) Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages, Antimicrobial Agents and Chemotherapy, 34 (8), 1508-11
• Grosset JH, Ji BH, Guelpa-Lauras CC, Perani EG, N'Deli LN (Jun 1990) Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 58 (2), 281-95
• Abel L, Cua VV, Oberti J, Lap VD, Due LK, Grosset J, Lagrange PH (Jun 1990) Leprosy and BCG in southern Vietnam, Lancet, 335 (8704), 1536
• Grosset J (Mar 1990) [Bacteriologic basis for the treatment of tuberculosis], La Revue Du Praticien, 40 (8), 715-8
• N'Deli L, Guelpa-Lauras CC, Perani EG, Grosset JH (Mar 1990) Effectiveness of pefloxacin in the treatment of lepromatous leprosy, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 58 (1), 12-8
• Grosset J (Jun-Sep 1990) Present and new drug regimens in chemotherapy and chemoprophylaxis of tuberculosis, Bulletin of the International Union Against Tuberculosis and Lung Disease, 65 (2-3), 86-91
• Grosset J, Boisvert H, Truffot-Pernot C, Rica C (Jun-Sep 1990) Organization of laboratory services in low prevalence countries, our personal view, Bulletin of the International Union Against Tuberculosis and Lung Disease, 65 (2-3), 60-3
• Grosset J ( -91 1990) New experimental regimens for preventive therapy of tuberculosis, , , 15-6 pages
• Cartel JL, Chanteau S, Boutin JP, Taylor R, Plichart R, Roux J, Celerier P, Grosset JH (Dec 1989) Implementation of chemoprophylaxis of leprosy in the Southern Marquesas with a single dose of 25 mg per kg rifampin, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 57 (4), 810-6
• Lecoeur HF, Truffot-Pernot C, Grosset JH (Nov 1989) Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide, The American Review of Respiratory Disease, 140 (5), 1189-93
• Rouby JJ, Rossignon MD, Nicolas MH, Martin de Lassale E, Cristin S, Grosset J, Viars P (Nov 1989) A prospective study of protected bronchoalveolar lavage in the diagnosis of nosocomial pneumonia, Anesthesiology, 71 (5), 679-85
• Truffot-Pernot C, Lecoeur HF, Maury L, Dautzenberg B, Grosset J (Sep 1989) Results of blood cultures for detection of mycobacteria in AIDS patients, Tubercle, 70 (3), 187-91
• Grosset JH, Guelpa-Lauras CC, Bobin P, Brucker G, Cartel JL, Constant-Desportes M, Flageul B, Frederic M, Guillaume JC, Millan J (Sep 1989) Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 57 (3), 607-14
• Jarlier V, Nicolas MH, Philippon A, Giroir AM, Grosset J (Aug 1989) In-vitro activity of FCE 22101 and other beta-lactam antibiotics against Enterobacteriaceae resistant to third generation cephalosporins, The Journal of Antimicrobial Chemotherapy, 24 (2), 165-72
• Grosset JH, Baohang J, Noordeen SK (Jul 1989) Comments on an editorial by B. R. Chatterjee "On Multi-Drug Combinations in the Treatment of Leprosy", Indian Journal of Leprosy, 61 (3), 323-7
• Grosset JH, Ji BH (Jun 1989) Controlled clinical trial for evaluation of antimicrobial drug activity against M. leprae, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 57 (2), 529-31
• Lecoeur HF, Lagrange PH, Truffot-Pernot C, Gheorghiu M, Grosset J (Jun 1989) Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice, Clinical and Experimental Immunology, 76 (3), 458-62
• Grosset JH (Mar-Apr 1989) Present status of chemotherapy for tuberculosis, Reviews of Infectious Diseases, 11 Suppl 2, S347-52
• Mitchison DA, Ellard GA, Grosset J (Jul 1988) New antibacterial drugs for the treatment of mycobacterial disease in man, British Medical Bulletin, 44 (3), 757-74
• Grosset JH, Truffot-Pernot C, Lecoeur H (Jun 1988) [New and future drugs in pulmonary tuberculosis], Praxis Und Klinik Der Pneumologie, 42 Suppl 1, 206-10
• Grosset JH, Guelpa-Lauras CC, Perani EG, Beoletto C (Jun 1988) Activity of ofloxacin against Mycobacterium leprae in the mouse, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 56 (2), 259-64
• Parrot RG, Grosset JH (Mar 1988) Post-surgical outcome of 57 patients with Mycobacterium xenopi pulmonary infection, Tubercle, 69 (1), 47-55
• Dautzenberg B, Grosset J (1988) [Tuberculosis and pregnancy], Revue Des Maladies Respiratoires, 5 (3), 279-83
• Lepetit C, Thebaud-Mony A, Grosset J (1988) [Tuberculosis in the Department of Seine-Saint Denis. I. Cases under treatment in 1984], Revue Des Maladies Respiratoires, 5 (2), 129-36
• Truffot-Pernot C, Giroir AM, Maury L, Grosset J (1988) [Study of the minimal inhibitory concentration of rifabutine (Ansamycin LM 427) for Mycobacterium tuberculosis, Mycobacterium xenopi and Mycobacterium avium-intracellulare], Revue Des Maladies Respiratoires, 5 (4), 401-6
• Cartel JL, Boutin JP, Plichart R, Roux J, Grosset JH (1988) [Leprosy in the French Polynesian archipelagoes from 1967 to 1987], Bulletin De La Societe De Pathologie Exotique Et De Ses Filiales, 81 (5), 819-26
• Grosset JH, Guelpa-Lauras CC (Dec 1987) Activity of rifampin in infections of normal mice with Mycobacterium leprae, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 55 (4 Suppl), 847-51
• Grosset JH, Baohong J, Ito T (Dec 1987) The first joint THELEP-Sasakawa Memorial Health Foundation workshop on experimental chemotherapy of leprosy, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 55 (4 Suppl), 807-13
• Cartel JL, Naudillon Y, Remy JC, Grosset JH (Dec 1987) Contribution of relapses to total infection sources of leprosy in Guadeloupe, Leprosy Review, 58 (4), 339-48
• McDermott-Lancaster RD, Ito T, Kohsaka K, Guelpa-Lauras CC, Grosset JH (Dec 1987) Multiplication of Mycobacterium leprae in the nude mouse, and some applications of nude mice to experimental leprosy, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 55 (4 Suppl), 889-95
• Mouquet C, Fusciardi J, Stoupak MP, Vallancien G, Jarlier V, Chatelain C, Grosset J, Viars P (Nov 1987) [Transurethral surgery and persistent urinary infection: effect of a single preoperative dose of cefuroxime], Pathologie-biologie, 35 (9), 1243-7
• Guelpa-Lauras CC, Perani EG, Giroir AM, Grosset JH (Mar 1987) Activities of pefloxacin and ciprofloxacin against Mycobacterium leprae in the mouse, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 55 (1), 70-7
• Grosset J, Lecoeur H (Jul-Sep 1987) [Present status of vaccination against leprosy], Acta Leprologica, 5 (3), 231-9
• Grosset J, Guelpa-Lauras CC, Millan J, Bodian M, Perani E (Apr-Jun 1987) [Resistance of Mycobacterium leprae to dapsone and rifampicin: apropos of a survey carried out in the Cape Verde region (Senegal)], Medecine Tropicale : Revue Du Corps De Sante Colonial, 47 (2), 171-5
• Jarlier V, Soussy CJ, Chanal M, Sirot D, Le Van Thoi J, Bismuth R, Grosset J, Duval J, Cluzel R (Dec 1986) [In vitro effect of piperacillin on aerobic bacteria. Variations according to the phenotypes of resistance to beta-lactam antibiotics], Presse Medicale (paris, France : 1983), 15 (46), 2272-8
• Dautzenberg B, Gallinari C, Aeberhardt G, Levy A, Bernheim J, Grosset J, Sors C (Dec 1986) [Routine use of 6-month antitubercular treatment in 300 patients], Presse Medicale (paris, France : 1983), 15 (43), 2151-2, 2157-8
• Choudat D, Horreard P, Pretet S, Grosset J, Toty L (Mar 1986) Superinfection by Aspergillus fumigatus of a pulmonary lesion caused by Mycobacterium xenopi, Tubercle, 67 (1), 71-4
• Grosset JH (1986) Recent developments in the field of multidrug therapy and future research in chemotherapy of leprosy, Leprosy Review, 57 Suppl 3, 223-34
• Grosset J, Lecoeur H (Jul-Sep 1986) [Vaccination against leprosy], Acta Leprologica, 4 (3), 289-91
• Sebille A, Crepon MO, Guelpa CC, Grosset J (Apr-Jun 1986) [Electrophysiologic demonstration of the activity of rifampicin on nerve disease developing in mice inoculated with Hansen's bacilli in the footpad], Acta Leprologica, 4 (2), 215
• Cartel JC, Gallais JJ, Naudillon Y, Millan J, Grosset JH (Oct-Dec 1986) [5-year assessment of daily multi-drug therapy of leprosy in Guadeloupe since 1980], Acta Leprologica, 4 (4), 415-25
• Cartel JL, Gallais JJ, Naudillon Y, Remy JG, Grosset JH (Apr-Jun 1986) [Epidemiology of leprosy in Guadeloupe from 1970 to 1984], Acta Leprologica, 4 (2), 161-73
• Constant-Desportes-Relouzat M, Grosset J, Guelpalauras CC, Salvini B, Cales-Quist D (Jul-Sep 1986) [Dynamics of establishing resistance of M. leprae to dapsone and rifampicin in Martinique], Acta Leprologica, 4 (3), 293-300
• Millan J, Bodian M, Naudin JC, Diouf B, Boucher P, Ndoye B, Grosset J (Jan-Mar 1986) [A trial of polychemotherapy of leprosy in the Dakar region. Initial observations on the acceptability of the protocols used], Acta Leprologica, 4 (1), 19-35
• Millan J, Roux G, Loko S, Naudin JC, Boucher P, Bodian M, Camara M, Moreira-Diop T, Grosset J (Oct-Dec 1986) [Multi-drug therapy trials for leprosy in Senegal: first observations relative to liver tolerance of multibacillary patients. Therapeutic consequences], Acta Leprologica, 4 (4), 427-44
• Sebille A, Crepon MO, Guelpa CC, Grosset J (Sep 1985) Evidence for the activity of rifampin on the neuropathy of foot pad-inoculated mice with Mycobacterium leprae, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 53 (3), 481-3
• Sors C, Bouvet E, Grosset J, Perdrizet S, Pretet S (Sep 1985) [Aspects of tuberculosis in France], Revue De L'infirmiere, 35 (15), 29-34
• Cartel JL, Naudillon Y, Artus JC, Grosset JH (Mar 1985) Hepatotoxicity of the daily combination of 5 mg/kg prothionamide + 10 mg/kg rifampin, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 53 (1), 15-8
• Grosset J, Levy L, Rees RJ, Shepard CC (Mar 1985) Drug sensitivity testing of M. leprae, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 53 (1), 118-21
• Grosset J, Truffot-Pernot C, Poggi S, Lecoeur H, Chastang C (1985) [Prevention of resistance to rifampicin by pyrazinamide in experimental tuberculosis in the mouse], Revue Des Maladies Respiratoires, 2 (4), 205-8
• Grosset J (Apr-Jun 1985) Mechanisms of action of antituberculosis drugs in standard and short-course chemotherapy regimens, Revista De Igiena, Bacteriologie, Virusologie, Parazitologie, Epidemiologie, Pneumoftiziologie. Pneumoftiziologia, 34 (2), 108-15
• Grosset J (Apr-Jun 1985) Bacteriological bases of short-course chemotherapy, Revista De Igiena, Bacteriologie, Virusologie, Parazitologie, Epidemiologie, Pneumoftiziologie. Pneumoftiziologia, 34 (2), 103-7
• Nebout M, Grosset J (Jul-Sep 1985) [Present-day difficulties in the campaign against leprosy and proposals for its resumption in French-speaking Africa], Acta Leprologica, 3 (3), 233-7
• Cartel JL, Gallais JJ, Grosset JH (Oct-Dec 1985) [Acceptability, compliance and tolerance of daily polychemotherapy by leprosy patients in Guadeloupe], Acta Leprologica, 3 (4), 339-55
• Jarlier V, Bismuth R, Nicolas MH, Nguyen J, Truffot C, Grosset J (Sep 1984) Survey of the phenotypes of susceptibility to beta-lactams in Enterobacteriaceae at the Pitie-Salpetriere Hospital, The Journal of Antimicrobial Chemotherapy, 14 Suppl B, 59-65
• Jarlier V, Truffot-Pernot C, Grosset J (Jun 1984) [Potential value of the amoxicillin-clavulanic acid combination in general medicine, gynecology-obstetrics and pediatrics departments], Pathologie-biologie, 32 (5 Pt 2), 492-5
• Guelpa-Lauras CC, Grosset JH, Constant-Desportes M, Brucker G (Mar 1984) Nine cases of rifampin-resistant leprosy, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 52 (1), 101-2
• Dautzenberg B, Grosset J, Fechner J, Lucciani J, Debre P, Herson S, Truffot C, Sors C (Mar 1984) The management of thirty immunocompromised patients with tuberculosis, The American Review of Respiratory Disease, 129 (3), 494-6
• Giroulle H, Bernabeu L, Boisvert H, Truffot C, Grosset J (1984) [Pulmonary mycobacteriosis due to a non-chromogenic, slow-growing, unclassified mycobacterium], Revue Des Maladies Respiratoires, 1 (3), 161-4
• Grosset J (Jan-Mar 1984) [Advances in the chemotherapy of leprosy], Medecine Tropicale : Revue Du Corps De Sante Colonial, 44 (1), 17-22
• Cartel JL, Millan J, Guelpa-Lauras CC, Grosset JH (Dec 1983) Hepatitis in leprosy patients treated by a daily combination of dapsone, rifampin, and a thioamide, International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 51 (4), 461-5
• Grosset J, Truffot-Pernot C, Bismuth R, Lecoeur H (Jun 1983) [Recent data on the chemotherapy of experimental tuberculosis in the mouse], Bulletin of the International Union Against Tuberculosis, 58 (2), 90-6
• Bismuth R, Jarlier V, Grosset J (May 1983) [In vitro synergy between sulfamethoxazole and trimethoprim on strains of Staphylococcus aureus sensitive and resistant to methicillin], Pathologie-biologie, 31 (5), 429-33
• Jarlier V, Bismuth R, Grosset J (May 1983) [Cefotaxime, moxalactam and ceftriaxone: comparison of in vitro activity against hospital strains of Enterobacteriaceae belonging to the 4 principal phenotypes of sensitivity to beta-lactams], Pathologie-biologie, 31 (5), 336-42
• Grosset J, Truffot-Pernot C, Lecoeur H, Guelpa-Lauras CC (May 1983) [Activity of rifampicin administered daily and intermittently on experimental tuberculosis in mice], Pathologie-biologie, 31 (5), 446-50
• Cooreman J, Burghard G, Grosset J (1983) [Resistance of the Koch bacillus to antibacillary agents in the Department of the Lower Rhine], Revue Francaise Des Maladies Respiratoires, 11 (5), 699-704
• Truffot-Pernot C, Grosset J, Bismuth R, Lecoeur H (1983) [Activity of intermittently administered rifampicin and cyclopentyl rifamycin (or DL473) on experimental tuberculosis in the mouse], Revue Francaise Des Maladies Respiratoires, 11 (6), 875-82
• Parrot R, Boval C, Grosset J, Gaillard JP (1983) [Adjusting or not adjusting isoniazid dosage?], Revue Francaise Des Maladies Respiratoires, 11 (5), 705-12
• Grosset J, Leventis S (Jul-Aug 1983) Adverse effects of rifampin, Reviews of Infectious Diseases, 5 Suppl 3, S440-50
• Grosset J, Truffot C, Fermanian J, Lecoeur H (Jun 1982) [Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)], Pathologie-biologie, 30 (6), 444-8
• Grosset J, Truffot C, Boval C (Mar 1982) The role of low dosage prothionamide with and without 4,4'-diamino diphenyl sulphone for use with isoniazid in the treatment of experimental mouse tuberculosis, Tubercle, 63 (1), 37-43
• Sors C, Dautzenberg B, Grosset J (Mar 1982) [Duration of the treatment of tuberculosis in 1981], La Nouvelle Presse Medicale, 11 (11), 831
• Grosset J, Bismuth R, Nguyen J (1982) [Pharmacokinetic basis for antibiotic therapy in broncho-pulmonary bacterial infections (author's transl)], Revue Francaise Des Maladies Respiratoires, 10 (3), 195-203
• Nguyen J, Dautzenberg B, Grosset J, Sors C (1982) [Results of antibiotic sensitivity and "Streptococcus pneumoniae" serotype tests in the Pitie-Salpetriere hospital, France, 1979-1980 (author's transl)], Revue Francaise Des Maladies Respiratoires, 10 (2), 115-20
• Grosset J, Truffot-Pernot C (Sep-Dec 1982) [Laboratories: their role in the diagnosis and treatment of tuberculosis], Bulletin of the International Union Against Tuberculosis, 57 (3-4), 234-41
• Grosset J, Guelpa-Lauras CC, Lecoeur H (Jan-Jun 1982) [Current data on the bacteriology of leprosy], Acta Leprologica (86-87), 35-45
• Guelpa-Lauras CC, Grosset J, Truffot-Pernot C, Giroir AM (Jan-Jun 1982) [Comparative bactericidal action of rifampicin alone on M. tuberculosis and M. leprae], Acta Leprologica (86-87), 69-75
• Guelpa-Lauras CC, Constant-Desportes M, Millan J, Grosset J (Jan-Jun 1982) [Resistance of Mycobacterium leprae to sulfones (DDS) and rifampicin in recurring lepromatous leprosy in Martinique and Guadeloupe since February 1980], Acta Leprologica (86-87), 77-80
• Grosset J (Dec 1981) Studies in short-course chemotherapy for tuberculosis. Basis for short-course chemotherapy, Chest, 80 (6), 719-20
• Grosset J (May 1980) Bacteriologic basis of short-course chemotherapy for tuberculosis, Clinics in Chest Medicine, 1 (2), 231-41
• Grosset J (Jun 1979) [The bacteriological principles of tuberculosis treatments], La Revue Du Praticien, 29 (33), 2645-50
• Dautzenberg B, Nguyen J, Grosset J, Sors C (1979) [A comparative study of three procedures used for studying bronchopulmonary bacterial flora (author's transl)], Annales De Medecine Interne, 130 (8-9), 415-8
• Grosset J (Dec 1978) [Short term chemotherapy of tuberculosis. Current experimental findings in short term chemotherapy], Bulletin of the International Union Against Tuberculosis, 53 (4), 281-3
• Pretet S, Grosset J, Perdrizet S (Dec 1978) [Short term chemotherapy of tuberculosis. Evaluation of an 18-week-long treatment including pyrazinamide (preliminary results)], Bulletin of the International Union Against Tuberculosis, 53 (4), 260-1
• Grosset J (Mar 1978) The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy, Bulletin of the International Union Against Tuberculosis, 53 (1), 5-12
• Grosset J, Glaser P, Baud A, Bismuth R (Feb 1976) [Bacterial flora in pneumopathies and its significance in surgical resuscitation], Lille Medical : Journal De La Faculte De Medecine Et De Pharmacie De L'universite De Lille., 21 (2), 97-9
• Vayssairat M, Moulias R, Rameix P, Grosset J, Chomette G, Loeper J (Apr 1973) [Two new cases of pulmonary mycobacteriosis due to Mycobacterium xenopi], Annales De Medecine Interne, 124 (4), 309-12
• Canetti G, Le Lirzin M, Gay P, Thibier R, Kreis B, Grosset J (Apr-May 1972) [Primary resistance in adult pulmonary tuberculosis in France. 3d report of the study center on Primary Resistance: 1966-1970], Revue De Tuberculose Et De Pneumologie, 36 (3), 337-56
• Grosset J (Dec 1971) Georges Canetti (1911-1971), Bulletin of the International Union Against Tuberculosis, 46, 7-8
• Grosset J, Decroix G, Sors C (Jun 1971) [Tuberculosis due to Mycobacterium africanum in African negroes in the Paris area], Revue De Tuberculose Et De Pneumologie, 35 (4), 430-6
• Boulahbal F, Grosset J (1971) [Use of pyridinium cetyl bromide as a transport medium for tuberculous sputum. Preliminary study], Archives. Institut Pasteur D'algerie, 49, 51-9
• Larbaoui D, Chaulet P, Grosset J, Abderrahim K, Ait-Mesbah H (Dec 1970) The efficiency of methods of diagnosing pulmonary tuberculosis: an investigation in a chest clinic in Algiers, Tubercle, 51 (4), 403-11
• Canetti G, Grosset J, Le Lirzin M (Jun 1970) [Sterilization of tuberculous lesions under chemotherapy in humans. Main report], Bulletin of the International Union Against Tuberculosis, 43, 347-59
• Larbaoui D, Chaulet P, Grosset J, Abderrahim K, Zirout A (Jun 1970) [Controlled study of a bi-weekly treatment with isoniazid and ethionamide], Bulletin of the International Union Against Tuberculosis, 43, 282-8
• Larbaoui D, Chaulet P, Grosset J, Abderrahim K, Oussedik N, Coucke C, Benabdallah L (Jun 1970) [Intermittent treatment of "intractable chronic tuberculosis" by combined rifampicin-ethambutol: preliminary results of a controlled survey made in Algeria], Revue De Tuberculose Et De Pneumologie, 34 (4), 559-66
• Grosset J, Benhassine M (1970) [Thiacetazone (Tb-1): recent experimental and clinical data], Bibliotheca Tuberculosea, 26, 107-53
• de Beco O, Boulahbal F, Grosset J (1970) [Incidence of the bovine bacillus in human tuberculosis at Algiers in 1969], Archives. Institut Pasteur D'algerie, 48, 93-101
• Grosset J, Abderrahim K, Chaulet P, Larbaoui D (Dec 1968) [Results of bi-weekly treatment with isoniazid and streptomycine in 135 cases of pulmonary tuberculisis, in Algiers], Bulletin of the International Union Against Tuberculosis, 41, 325-30
• Chaulet P, Boulahbal M, Grosset J (Jun 1968) [Acquired resistance to antibiotics of the tuberculosis bacillus in the Algiers area from 1963 to 1967. Importance and epidemiologic significance], Revue De Tuberculose Et De Pneumologie, 32 (4), 542-51
• Grosset J, Benhassine M, Mokhtari L (Jun 1968) [Trial B.C.G. vaccination without previous tuberculin test in an Algiers outpatient clinic], Revue De Tuberculose Et De Pneumologie, 32 (4), 551-60
• Seror J, Grosset J (May 1968) [Apropos of a case of mesenteric adenitis caused by Eberth's bacillus], Annales De Chirurgie, 22 (9), 629-31
• Chaulet P, Abderrahim K, Grosset J, Larbaoui D (Mar 1968) Clinical experience in Algeria of intermittent treatment of pulmonary tuberculosis with isoniazid and streptomycin twice-weekly, Tubercle, 49, Suppl:81-2
• Grosset J, Rodrigues F, Benhassine M, Chaulet P, Larbaoui D (Mar 1968) Sensitivity to thiacetazone of strains of Mycobacterium tuberculosis isolated in Algiers: practical deductions, Tubercle, 49, Suppl:46-8
• Grosset J, Benhassine M (Jun 1967) [Antibiotic primary resistance of mycobacterium tuberculosis in hospitals in Algeria (1964-1966)], Revue De Tuberculose Et De Pneumologie, 31 (4), 475-90
• Chaulet P, Larbaoui D, Grosset J, Abderrahim K (Jun 1967) Intermittent chemotherapy with isoniazid and streptomycin in Algiers, Tubercle, 48 (2), 128-36
• Grumbach F, Canetti G, Grosset J, le Lirzin M (Mar 1967) Late results of long-term intermittent chemotherapy of advanced, murine tuberculosis: limits of the murine model, Tubercle, 48 (1), 11-26
• Canetti G, Rist N, Grosset J (Nov 1964) PRIMARY DRUG RESISTANCE IN TUBERCULOSIS, The American Review of Respiratory Disease, 90, 792-9
• Canetti G, Kreis B, Thibier R, Grosset J, Gluszyk J (Nov 1964) [INCIDENCE AND CHARACTERISTICS OF PRIMARY RESISTANCE IN 2144 CASES OF UNTREATED PULMONARY TUBERCULOSIS FROM DIFFERENT REGIONS OF FRANCE (PRELIMINARY REPORT OF THE CENTRE D'ETUDE SUR LA R'ESISTANCE PRIMAIRE)], Revue De Tuberculose Et De Pneumologie, 28, 1115-58
• Grumbach F, Canetti G, Grosset J (Jun 1964) FURTHER EXPERIMENTS ON LONG-TERM CHEMOTHERAPY OF ADVANCED MURINE TUBERCULOSIS, WITH EMPHASIS ON INTERMITTENT REGIMES., Tubercle, 45, 125-35
• Vivien Jn, Thibier R, Lepeuple A, Canetti G, Grosset J (Nov 1963) [SYSTEMATIC DETERMINATION OF ACTIVE ISONIAZID IN THE BLOOD SERUM. (DATA FROM A SERIES OF 1,000 PATIENTS)], Revue De Tuberculose Et De Pneumologie, 27, 1103-18
• Canetti G, Grumbach F, Grosset J (Jun 1963) Long-term, two-stage chemotherapy of advanced experimental murine tuberculosis with intermittent regimes during the second stage, Tubercle, 44, 236-40
• Canetti G, Grumbach F, Grosset J (Jun 1963) Long-term, two-stage chemotherapy of advanced experimental murine tuberculosis with intermittent regimes during the second stage, Tubercle, 44, 236-40
• Lepeuple A, Thibier R, Vivien Jn, Canetti G, Grosset J (Jan 1963) [Identification of the sources of contagion in various cases of primary tuberculosis resistance], Revue De Tuberculose Et De Pneumologie, 27, 53-66
• Canetti G, Froman S, Grosset J, Hauduroy P, Langerova M, Mahler Ht, Meissner G, Mitchison Da, Sula L (1963) MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE, Bulletin of the World Health Organization, 29, 565-78
• Canetti G, Rist N, Grosset J (Feb-Mar 1963) [Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation], Revue De Tuberculose Et De Pneumologie, 27, 217-72
• Thibier R, Lepeuple A, Vivien Jn, Grosset J (May-Jun 1963) [RESULTS OF CHEMOTHERAPY AMONG 221 PATIENTS WITH PULMONARY TUBERCULOSIS DUE TO BACILLI INITIALLY SENSITIVE TO PRINCIPAL ANTIBIOTICS (FOLLOW UP OF 2 TO 5 YEARS)], Revue De Tuberculose Et De Pneumologie, 27, 541-50
• Grosset J, Canetti G (Aug 1962) [Incidence of wild strains of Mycobacterium tuberculosis in variants resistant to minor antibiotics (p-aminosalicylic acid, ethionamide, cycloserine, viomycin, kanamycin)], Annales De L'institut Pasteur, 103, 163-84
• Thibier R, Canetti G, Lepeuple A, Grosset J, Vivien Jn (Jul 1962) [Tuberculosis caused by primary-resistant bacilli in university students during the years 1958-1960], Bulletin of the International Union Against Tuberculosis, 32, 113-7
• Vivien Jn, Thibier R, Lepeuple A, Grosset J (Sep-Oct 1962) [The exactness of the practical measurement of active serum isoniazid levels by the vertical diffusion microbiological method], Revue De Tuberculose Et De Pneumologie, 26, 978-88
• Grosset J, Canetti G (Aug 1961) [Differences in the number of streptomycin-resistant variants in strains of Mycobacterium tuberculosis according to the type of streptomycin and the culture medium used], Annales De L'institut Pasteur, 101, 234-52
• Canetti G, Grosset J (Jul 1961) [Percentage of isoniazid-resistant and streptomycin-resistant variants in wild strains of Mycobacterium tuberculosis on Loewenstein-Jensen medium], Annales De L'institut Pasteur, 101, 28-46
• Vivien Jn, Grosset J (1961) [The level of active isoniazid in the blood serum], Bibliotheca Tuberculosea, 16, 45-121
• Lepeuple A, Thibier R, Vivien Jn, Grosset J, Canetti G (Dec 1960) [A case of transmission of Koch bacilli from a tuberculous subject to a subject recovered from pulmonary tuberculosis], Rivista Di Chirurgia Pediatrica, 24, 1312-21
• Canetti G, Grumbach F, Grosset J (Sep 1960) Studies of bacillary populations in experimental tuberculosis of mice treated by isoniazid, The American Review of Respiratory Disease, 82, 295-313
• Canetti G, Grumbach F, Grosset J (Sep 1960) Studies of bacillary populations in experimental tuberculosis of mice treated by isoniazid, The American Review of Respiratory Disease, 82, 295-313
• Grumbach F, Grosset J, Canetti G (May 1960) [The inactivation of isoniazid in the rat. Its effects on the results of the chemotherapy of tuberculosis in that species], Annales De L'institut Pasteur, 98, 642-56
• Grosset J, Canetti G (May-Jun 1960) [Complementary data on the determination of active isoniazid of the blood serum by the method of vertical diffusion. Determination in presence of PAS], Revue De Tuberculose Et De Pneumologie, 24, 633-47
• Thibier R, Canetti G, Lepeuple A, Grosset J, Vivien Jn (Jul-Aug 1960) [Pulmonary tuberculosis with resistant bacilli in patients not yet treated], Rivista Di Clinica Pediatrica, 24, 831-68
• Canetti G, Bretey J, SAENZ A Jr, Grosset J (Sep 1958) [Effect of early treatment with isoniazid on the immunity induced in guinea pigs by a small dose of standard BCG; further data on the immunizing capacity of isoniazid-resistant BCG], Annales De L'institut Pasteur, 95 (3), 262-71
• Canetti G, Grosset J (Jul 1958) [Frequency of post-primary bronchial gland fistulas in 397 cases of pulmonary tuberculosis in adults treated by exeresis; discussion of their phthisiogenic role], Revue De La Tuberculose, 22 (7), 653-7
• Vivien Jn, Thibier R, Grosset J, Lepeuple A (Feb-Mar 1958) [Early results of isoniazid therapy as a function of the active blood level of isoniazid; study of 100 cases], Revue De La Tuberculose, 22 (2-3), 208-22
• Grosset J, Canetti G, Thibier R, Vivien Jn, Lepeuple J, SAENZ A Jr (Feb-Mar 1958) [Comparative effects of oral and intravenous p-aminosalicylic acid on the active blood level of isoniazid], Revue De La Tuberculose, 22 (2-3), 202-7
• Grosset J, Grumbach F, Canetti G (Jun 1957) [Modification of methods of biological measurement of isoniazid in blood serum; results in 53 cases], Annales De L'institut Pasteur, 92 (6), 752-9
• Canetti G, Grosset J (Dec 1956) [Late positivization of cultures of tuberculosis bacilli; its relation to isoniazid resistance], Revue De La Tuberculose, 20 (11-12), 1053-61
• Canetti G, Grosset J (Dec 1956) [Late positivization of cultures of tuberculosis bacilli; its relation to isoniazid resistance], Revue De La Tuberculose, 20 (11-12), 1053-61